Key Takeaways
- • KKR & Co. is in advanced negotiations to acquire Integer Holdings (ITGR), a Plano, Texas-based medical device outsourcer, at $127 per share, valuing the company at approximately $4.3 billion.
- • Integer Holdings shares surged approximately 20–21% on the Wall Street Journal report of the pending acquisition, reflecting significant upside from the proposed offer price.
- • A deal announcement could occur as soon as the following week from the July 31, 2026 report date, indicating advanced stages of negotiation.
- • Integer Holdings has faced activist investor pressure prior to this transaction, positioning the KKR bid as a potential resolution to stakeholder demands.
- • Year-to-date performance shows Integer shares gained 54% prior to the KKR report, suggesting market anticipation of strategic developments.
Summary
KKR & Co., the global investment firm, is nearing a definitive agreement to acquire Integer Holdings Corporation, a leading medical device contract manufacturer and outsourcer based in Plano, Texas. According to reporting from The Wall Street Journal on July 31, 2026, the private equity firm is offering $127 per share in cash for the company, which values Integer at approximately $4.3 billion based on the company's outstanding share count of 33.95 million shares.
Market reaction to the reported transaction was immediate and substantial. Integer Holdings shares surged approximately 20–21% in trading following the Wall Street Journal's disclosure, reflecting investor confidence in the proposed valuation and deal execution. The stock's rally represents meaningful upside recognition, particularly given that Integer shares had already appreciated 54% year-to-date prior to the acquisition report, suggesting the market had begun pricing in potential strategic alternatives.
The timeline for deal completion appears compressed. Multiple sources indicate that a formal announcement could materialize as soon as the week following the report, positioning this as a near-term catalytic event. The accelerated timeline suggests the parties have advanced significantly through legal, financial, and regulatory due diligence phases. Integer Holdings had previously been subject to activist investor pressure, a factor that likely contributed to management's receptiveness to a third-party acquisition at a premium valuation.
The transaction, if completed at the proposed terms, would provide liquidity to Integer shareholders while enabling KKR to acquire a diversified platform in the medical device outsourcing sector—a defensive, recurring-revenue business model aligned with long-term demographic trends in healthcare. As of the report date, definitive documentation had not been executed, and regulatory approval and customary closing conditions would remain pending.
Market reaction to the reported transaction was immediate and substantial. Integer Holdings shares surged approximately 20–21% in trading following the Wall Street Journal's disclosure, reflecting investor confidence in the proposed valuation and deal execution. The stock's rally represents meaningful upside recognition, particularly given that Integer shares had already appreciated 54% year-to-date prior to the acquisition report, suggesting the market had begun pricing in potential strategic alternatives.
The timeline for deal completion appears compressed. Multiple sources indicate that a formal announcement could materialize as soon as the week following the report, positioning this as a near-term catalytic event. The accelerated timeline suggests the parties have advanced significantly through legal, financial, and regulatory due diligence phases. Integer Holdings had previously been subject to activist investor pressure, a factor that likely contributed to management's receptiveness to a third-party acquisition at a premium valuation.
The transaction, if completed at the proposed terms, would provide liquidity to Integer shareholders while enabling KKR to acquire a diversified platform in the medical device outsourcing sector—a defensive, recurring-revenue business model aligned with long-term demographic trends in healthcare. As of the report date, definitive documentation had not been executed, and regulatory approval and customary closing conditions would remain pending.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.